US Stock MarketDetailed Quotes

MRVI Maravai LifeSciences

Watchlist
  • 5.670
  • -0.250-4.22%
Close Nov 29 13:00 ET
  • 5.800
  • +0.130+2.29%
Post 17:02 ET
804.25MMarket Cap-3395P/E (TTM)

About Maravai LifeSciences Company

Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.

Company Profile

SymbolMRVI
Company NameMaravai LifeSciences
Listing DateNov 20, 2020
Issue Price27.00
Founded2014
CEOMr. William Martin, III
MarketNASDAQ
Employees650
Fiscal Year Ends12-31
Address10770 Wateridge Circle,Suite 200
CitySan Diego
ProvinceCalifornia
CountryUnited States of America
Zip Code92121
Phone1-858-546-0004

Company Executives

  • Name
  • Position
  • Salary
  • William Martin, III
  • Chief Executive Officer and Director
  • 2.30M
  • Rebecca Buzzeo
  • Executive Vice President and Chief Commercial Officer
  • --
  • Kevin Herde
  • Chief Financial Officer and Principal Accounting Officer
  • 2.79M
  • Dr. Peter M. Leddy, PhD
  • Chief Administrative Officer
  • 2.83M
  • Christine Dolan
  • Executive Vice President and General Manager, Cygnus Technologies
  • 2.26M
  • Carl W. Hull
  • Executive Chairman of the Board
  • 5.22M
  • Andrew Burch
  • President, Nucleic Acid Production
  • 2.99M
  • Luke Marker
  • Director
  • 360.48K
  • Benjamin Daverman
  • Director
  • 360.48K
  • Constantine S. Mihas
  • Director
  • 370.48K
  • Sean L. Cunningham
  • Director
  • 367.98K
  • Gregory T. Lucier
  • Independent Director
  • 360.48K
  • Dr. Murali K. Prahalad, PhD
  • Independent Director
  • 367.98K
  • Dr. John A. DeFord, PhD
  • Independent Director
  • 435.03K
  • Dr. Jessica Hopfield, PhD
  • Independent Director
  • 387.98K
  • Susannah Gray, M.B.A.
  • Independent Director
  • 395.48K
  • Kurt Oreshack
  • General Counsel and Secretary
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data